FDA Will Require use of Research Performance Progress Report (RPPR) for All Grant/Cooperative Agreement Awards

Notice Number: NOT-FD-16-014

Key Dates
Release Date:  August 2, 2016

Related Announcements
None    

Issued by
U.S. Food and Drug Administration (FDA)

Purpose

All Food and Drug Administration (FDA) grantees will have the ability to use the eRA Commons Research Performance Progress Report (RPPR) module beginning October 1, 2016.  Effective October 1, 2016, FDA will require use of the RPPR module to submit Type 5 Progress Reports and Final Progress Reports.  Implementation of the RPPR will replace the PHS Non-competing Continuation Progress Report (PHS 2590).

FDA's use of the RPPR format will not differ significantly from NIH’s, and FDA grantees are encouraged to utilize the resources posted on the NIH RPPR webpage (see https://grants.nih.gov/grants/rppr/), especially the webinars, NIH and Other PHS Agency RPPR Instruction Guide, and screen shots.  

Inquiries

General questions concerning using the eRA Commons and RPPR functionality should be directed to the eRA Commons Helpdesk at:

eRA Commons Help Desk
Web: http://ithelpdesk.nih.gov/eRA/ (Preferred method of contact)
Toll-free: 1-866-504-9552
Phone: 301-402-7469
TTY: 301-451-5939
Hours: Mon-Fri, 7a.m. to 8 p.m. Eastern Standard Time

General questions concerning this Notice may be directed to:

Food and Drug Administration (FDA)
Office of Acquisitions and Grants Services
Grants Management Branch
Email:  OAGSGrantsPolicy@fda.hhs.gov